Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion
- 1 February 2019
- journal article
- letter
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (2) , e29-e30
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung CancerJournal of Clinical Oncology, 2018
- Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Tyrosine kinase gene rearrangements in epithelial malignanciesNature Reviews Cancer, 2013
- MEK1 inactivates Myt1 to regulate Golgi membrane fragmentation and mitotic entry in mammalian cellsThe EMBO Journal, 2012